Abionyx Pharma SA Sustainability Reports

ABIONYX Pharma SA is a French biopharmaceutical company that focuses on the discovery and development of innovative therapies for metabolic, renal, and ophthalmological diseases. Its primary pipeline candidate is CER-001, a recombinant high-density lipoprotein (HDL) mimetic designed for treating sepsis and LCAT deficiency.

Sector: Professional & technical services

Country: France

Exchange: Euronext Paris

LEI: 969500785J7VIC5YPC96

FIGI: BBG001T6Y4G9

12 reports from 2015 to 2025

• Abionyx Pharma SA 2025 Universal Registration Document
• Abionyx Pharma SA 2025 Universal Registration Document
• Abionyx Pharma SA 2024 Universal Registration Document
• Abionyx Pharma SA 2023 Universal Registration Document
• Abionyx Pharma SA 2022 Universal Registration Document Including Annual Financial Report